# Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)

> **NCT04930055** · — · TERMINATED · sponsor: **Indiana University** · enrollment: 2206 (actual)

## Conditions studied

- Cancer

## Interventions

- **BIOLOGICAL:** COVID-19 Vaccination

## Key facts

- **NCT ID:** NCT04930055
- **Lead sponsor:** Indiana University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-30
- **Primary completion:** 2021-11-01
- **Final completion:** 2022-03-08
- **Target enrollment:** 2206 (ACTUAL)
- **Why stopped:** PI had decided to terminate the study
- **Last updated:** 2023-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04930055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04930055, "Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04930055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*